ihacares.com
Jun 15, 2023, 15:56
Patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes – Elie G. Dib
Excited to share that our study, published in JCO Precision Oncology, sheds light on the antitumor activity of pertuzumab plus trastuzumab (P + T) in advanced lung cancer patients with ERBB2 mutation or amplification. The Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrated promising results, with a disease control rate of 37% and an objective response rate of 11%. Notably, patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes. These findings offer hope for heavily pretreated non-small-cell lung cancer patients. Grateful to the team and the American Society of Clinical Oncology for their support.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 27, 2025, 07:45
Feb 26, 2025, 16:32
Feb 26, 2025, 16:31